Abstract | PURPOSE: SUMMARY:
Nivolumab is a novel programmed cell death 1 (PD-1) immune checkpoint inhibitor indicated as a second-line treatment for patients with NSCLC whose tumors exhibit squamous cell histology. Nivolumab has high affinity for the PD-1 receptor, and durable responses to treatment have been reported in clinical trials. In a Phase II study evaluating the drug's safety and efficacy in patients who had disease progression despite treatment with platinum-based doublet chemotherapy and at least one additional systemic therapy, nivolumab-treated patients had an objective response rate of 14.5%, with a 17% rate of grade 3 or 4 treatment-related adverse events; overall survival at one year was 40.8%. A head-to-head comparison of docetaxel and nivolumab for second-line treatment of squamous cell NSCLC demonstrated superior overall survival and reduced grade 3 or 4 adverse effects in nivolumab-treated patients. CONCLUSION:
|
Authors | Amanda Rounds, Jill Kolesar |
Journal | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
(Am J Health Syst Pharm)
Vol. 72
Issue 21
Pg. 1851-5
(Nov 01 2015)
ISSN: 1535-2900 [Electronic] England |
PMID | 26490818
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Nivolumab
|
Topics |
- Antibodies, Monoclonal
(economics, therapeutic use)
- Antineoplastic Agents
(economics, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Carcinoma, Squamous Cell
(drug therapy)
- Clinical Trials as Topic
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Humans
- Lung Neoplasms
(drug therapy)
- Nivolumab
|